Search Results - "Schluep, T."

Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen by Yuen, M.-F, Liu, K, Chan, H.L, Given, B.D, Schluep, T, Hamilton, J, Lai, C.-L, Locarnini, S.A, Lau, J.Y, Ferrari, C, Gish, R.G

Get full text

A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population by Gane, E, Schwabe, C, Given, B, Schluep, T, Hamilton, J, Lai, C.-L, Locarnini, S, Lau, J, Ferrari, C, Gish, R

Get full text

Predicting HBsAg Clearance Responses during ARC-520 RNA Interference (RNAI) Therapy Based on HBsAg Epitope Profile Analysis by Walsh, R, Hammond, R, Yuen, L, Deerain, J, Given, B, Schluep, T, Yuen, M.-F, Chan, H.L.-Y, Lai, C.-L, Hamilton, J, Lau, J.Y, Ferrari, C, Gish, R.G, Locarnini, S.A

Get full text

Differential Reductions in Viral Antigens Expressed from CCCDNAVS Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520 by Yuen, M.-F, Chan, H.L.Y, Liu, K, Given, B.D, Schluep, T, Hamilton, J, Lai, C.-L, Locarnini, S.A, Lau, J.Y.N, Ferrari, C, Gish, R.G

Get full text

Purification of plasmids by triplex affinity interaction by Schluep, Thomas, Cooney, Charles L.

“…Production of pharmaceutical grade plasmid DNA is an important issue in gene therapy. We developed a method for affinity purification of plasmids by triple…”
Get full text

423 Phase 1 dose escalation, safety and pharmacokinetic study of IT-101 (CRLX101), a novel nanopharmaceutical containing camptothecin, in advanced solid tumor cancer patients by Yen, Y, Synold, T, Weiss, G.J, Schluep, T, Ryan, J

Get full text

PS-030 - Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection by Wooddell, C., Zhu, R., Hamilton, H., Chu, Q., Sternard, H., Schumacher, J., Schluep, T., Seefeld, M., Li, Z., Given, B.

Get full text

Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection by Wooddell, C., Zhu, R., Hamilton, H., Chu, Q., Sternard, H., Schumacher, J., Schluep, T., Seefeld, M., Li, Z., Given, B.

Get full text

RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV by Yuen, M.-F., Liu, K., Given, B., Schluep, T., Hamilton, J., Lai, C.L., Locarnini, S., Jackson, K., Lau, J.Y., Ferrari, C., Gish, R.G.

Get full text

FRI-362 - RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV by Yuen, M.-F., Liu, K., Given, B., Schluep, T., Hamilton, J., Lai, C.L., Locarnini, S., Jackson, K., Lau, J.Y., Ferrari, C., Gish, R.G.

Get full text

Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models by SCHLUEP, Thomas, HWANG, Jungyeong, JIANJUN CHENG, HEIDEL, Jeremy D, BARTLETT, Derek W, HOLLISTER, Beth, DAVIS, Mark E

“…Preclinical efficacy of i.v. IT-101, a nanoparticulate conjugate of 20( S )-camptothecin and a cyclodextrin-based polymer, was investigated in several mouse…”
Get full text

PS-045 - Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen by Yuen, M.-F., Liu, K., Chan, H.L., Given, B.D., Schluep, T., Hamilton, J., Lai, C.-L., Locarnini, S.A., Lau, J.Y., Ferrari, C., Gish, R.G.

Get full text

THU-176 - A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population by Gane, E., Schwabe, C., Given, B., Schluep, T., Hamilton, J., Lai, C.-L., Locarnini, S., Lau, J., Ferrari, C., Gish, R.

Get full text

THU-193 - Differential Reductions in Viral Antigens Expressed from CCCDNAVS Integrated DNA in Treatment Naïve HBEAG Positive and Negative Patients with Chronic HBV after RNA Interference Therapy with ARC-520 by Yuen, M.-F., Chan, H.L.Y., Liu, K., Given, B.D., Schluep, T., Hamilton, J., Lai, C.-L., Locarnini, S.A., Lau, J.Y.N., Ferrari, C., Gish, R.G.

Get full text

WS09.4 Targeting αENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis by Bush, E.W., Nicholas, A., Pei, T., Kuipers, I., Cheng, W., Hamilton, H., Hegge, J., Li, X., Glebocka, A., Zhu, R., Chen, B., Kuehl, P., Schluep, T., Li, Z.

Get full text

Cyclodextrin-Modified Polyethylenimine Polymers for Gene Delivery by Pun, Suzie H, Bellocq, Nathalie C, Liu, Aijie, Jensen, Greg, Machemer, Todd, Quijano, Erlinda, Schluep, Thomas, Wen, Shufen, Engler, Heidrun, Heidel, Jeremy, Davis, Mark E

“…Linear and branched poly(ethylenimines), lPEI and bPEI, respectively, grafted with β-cyclodextrin are prepared to give CD−lPEI and CD−bPEI, respectively, and…”
Get full text

Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice by SCHLUEP, Thomas, JIANJUN CHENG, KHIN, Kay T, DAVIS, Mark E

“…IT-101 is a camptothecin-polymer conjugate prepared by linking camptothecin (CPT) to a hydrophilic, cyclodextrin-based, linear polymer through ester bonds. In…”
Get full text

FRI-144 - Predicting HBsAg Clearance Responses during ARC-520 RNA Interference (RNAI) Therapy Based on HBsAg Epitope Profile Analysis by Walsh, R., Hammond, R., Yuen, L., Deerain, J., Given, B., Schluep, T., Yuen, M.-F., Chan, H.L.-Y., Lai, C.-L., Hamilton, J., Lau, J.Y., Ferrari, C., Gish, R.G., Locarnini, S.A.

Get full text

Preparative purification of supercoiled plasmid DNA using anion-exchange chromatography by Prazeres, Duarte Miguel F, Schluep, Thomas, Cooney, Charles

“…Large scale manufacturing of gene vectors such as plasmid DNA is an important issue in gene therapy. Anion-exchange chromatography is fundamental in the…”
Get full text

A dose-finding pharmacokinetic study of IT-101, the first de novo designed nanoparticle therapeutic, in refractory solid tumors by Oliver, J. C., Yen, Y., Synold, T. W., Schluep, T., Davis, M.

“…Abstract only…”
Get full text